Upgrade to SI Premium - Free Trial

Merck (MRK) Reports Positive Opinion from EMA for KEYTRUDA (pembrolizumab) Combination with Pemetrexed & Platinum Chemotherapy

July 30, 2018 6:47 AM
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Management Comments

Next Articles